TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38769284
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate 3-month (PP3M) injection
Study: 38769330
Drug: Ciprofloxacin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg q 12 hourly) plus Metronidazole (800 mg q 8 hourly) for 2 weeks
Study: 38769330
Drug: Cefixime (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime (200 mg q 12 hourly) plus Metronidazole (800 mg q 8 hourly) for 2 weeks
Study: 38769543
Drug: Modified TIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified TIL therapy regimen (low-dose cyclophosphamide lymphodepletion followed by TIL infusion without intravenous IL-2)
Study: 38769543
Drug: Modified TIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified TIL therapy regimen
Study: 38769624
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no guidance for therapies)
Study: 38769974
Drug: SARS-CoV-2 mRNA
Normalized name: SARS-CoV-2 mRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2 mRNA vaccine booster dose (third vaccine dose)
Study: 38770592
Drug: Deucravacitinib at
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib at 6 mg QD
Study: 38770592
Drug: Deucravacitinib at
Normalized name: Deucravacitinib
DrugBank: Deucravacitinib (DB16650)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deucravacitinib at 12 mg QD
Study: 38770686
Drug: Daily Cannabidiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Cannabidiol Administration
Study: 38771152
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of curcuminoids in turmeric extract capsules and acupressure (group 1)
Study: 38771622
Drug: Improving Pediatric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improving Pediatric Obesity Practice Using Prompts (integrated package comprising CDS for obesity treatment)
Study: 38771808
Drug: Aortic Valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aortic Valve Improved Treatment Approaches (AVITA), an interactive, online decision aid
Study: 38771808
Drug: Aortic Valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aortic Valve Improved Treatment Approaches (AVITA)
Study: 38771973
Drug: Distinct types
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distinct types of therapy activity preferences
Study: 38771973
Drug: No specific
Normalized name: Oregano specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: No specific therapy activity or preference
Study: 38771995
Drug: Ribociclib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib plus endocrine therapy (ET) (600 mg once daily; 3 weeks on, 1 week off)
Study: 38771995
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CT) (docetaxel plus capecitabine, paclitaxel plus gemcitabine, or capecitabine plus vinorelbine)
Study: 38772477
Drug: Ablative stereotactic
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative stereotactic body radiation therapy (SBRT) delivered using a risk adaptive approach (50 Gy/5 fractions, 60 Gy/8 fractions, 70 Gy/10 fractions)
Study: 38772477
Drug: Ablative stereotactic
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative stereotactic body radiation therapy (SBRT)
Study: 38772883
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg Dimethyl fumarate (DMF) orally every day for 6 months
Study: 38772883
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg Dimethyl fumarate (DMF)
Study: 38772898
Drug: ACT intervention
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT intervention (Advance Consultations Concerning your Life and Treatment)
Study: 38773199
Drug: Glycine 0.5
Normalized name: GLYCINE 0.5 g in 100 g DENTAL PASTE, DENTIFRICE [CAREDO Treating Gingivitis Toothpastes 100g]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycine 0.5 g/kg/day by enteral route
Study: 38773457
Drug: Preoperative concurrent
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative concurrent chemoradiotherapy (preCRT) with raltitrexed (3 mg/m2 on days 1 and 22) and radiotherapy (50 Gy)
Study: 38773457
Drug: Preoperative concurrent
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative concurrent chemoradiotherapy (preCRT)
Study: 38773528
Drug: Primaquine (PQ)
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Primaquine (PQ) 0.4-0.5 mg/kg
Study: 38773543
Drug: Very low-energy
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low-energy diets (VLEDs); specific dosage and duration not mentioned.
Study: 38773643
Drug: Stereotactic radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stereotactic radiotherapy (SRT) treatment (24 Gy, single fraction)
Study: 38773643
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (continuation of anti-seizure medication and neuromodulation)
Study: 38773653
Drug: Intravenous 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 2% lidocaine bolus of 1.5 mg/kg with induction of anesthesia, followed by a 2.0 mg/kg/h infusion until the end of surgery
Study: 38773653
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution (normal saline) at the same volume
Study: 38773653
Drug: Intravenous 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 2% lidocaine
Study: 38773662
Drug: Telemedicine home-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telemedicine home-based management program including support from a nursing case manager, daily physical activity stimulation, teleconsultations, telemonitoring, and an app for monitoring clinical parameters.
Study: 38774010
Drug: Tafamidis (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafamidis (20 mg and 80 mg pooled)
Study: 38774037
Drug: Extended-release once-nightly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release once-nightly sodium oxybate (ON-SXB)
Study: 38774425
Drug: Direct factor
Normalized name: Direct factor Xa inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct factor Xa inhibitors (apixaban, edoxaban, rivaroxaban)
Study: 38774484
Drug: Intranasal remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal remimazolam 1.5mg/kg
Study: 38774675
Drug: BCG-Denmark (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG-Denmark (single 0.1 ml intradermal injection)
Study: 38774780
Drug: Behavioral Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Activation (BA) therapy for 9 weeks
Study: 38775275
Drug: Weekly surveys
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly surveys and biweekly nasal sampling
Study: 38775632
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored oral health intervention provided by a dental hygienist focusing on oral hygiene and self-care.
Study: 38775910
Drug: Fixed-Dose Combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-Dose Combination Product (FDCP) of amlodipine, losartan, ezetimibe, and rosuvastatin
Study: 38775910
Drug: Individual tablets
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual tablets of amlodipine, losartan, ezetimibe, and rosuvastatin
Study: 38775910
Drug: Fixed-Dose Combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-Dose Combination Product (FDCP)
Study: 38776391
Drug: BNT142 RNA-LNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT142 RNA-LNP (0.1- to 1-μg dose range)
Study: 38776484
Drug: Ruxolitinib 15
Normalized name: ruxolitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 15 mg PO twice a day with paclitaxel/carboplatin chemotherapy
Study: 38776484
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (paclitaxel/carboplatin)
Study: 38776515
Drug: Treatment options
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment options based on PROSPECT trial data
Study: 38776517
Drug: Artificial intelligence
Normalized name: Intelence
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artificial intelligence in treatment planning
Study: 38776543
Drug: Antimicrobial Photodynamic
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial Photodynamic Therapy (a specific intervention for root canal disinfection)
Study: 38776635
Drug: Intervention M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention M (influenza vaccine messaging platform: video, flyer, scripted message, vaccine acceptance question, provider notification)
Study: 38776635
Drug: Intervention Q
Normalized name: Chew Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention Q (no messaging, vaccine acceptance question, provider notification)
Study: 38776754
Drug: Dietary sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary sulfur amino acid restriction (SAAR) (∼2 g SAA)
Study: 38776754
Drug: Control diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control diet (∼5.6 g SAA)
Study: 38776914
Drug: Iberdomide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide treatment
Study: 38777276
Drug: Maudsley Staging
Normalized name: fluorexon stain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maudsley Staging Method treatment-resistance scores
Study: 38778264
Drug: Morning light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning light treatment for 4 weeks
Study: 38778264
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) for 4 weeks
Study: 38778803
Drug: ECPR treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECPR treatment
Study: 38779740
Drug: Defibrotide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide (25 mg/kg intravenously, divided into four daily doses over 14 days)
Study: 38779911
Drug: Targeted treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted treatments based on molecular profiling (24 drugs available)
Study: 38780185
Drug: App-based mental
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based mental training (MT) for 3 months, daily 10-minute sessions
Study: 38780927
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg IV every 2 weeks for 5 cycles during IMRT, then 480 mg IV every 4 weeks for a total of 52 weeks)
Study: 38780959
Drug: Combined Airway
Normalized name: inBreath airway transplant system
DrugBank: inBreath airway transplant system (DB18692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Airway and Positional Therapy (CAPT)
Study: 38781428
Drug: Secondary mitral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary mitral regurgitation (MR) with MR volume ≥ 24 mL
Study: 38781591
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (maintained on antihypertensive therapy with a goal BP below 140/90 mm Hg)
Study: 38781634
Drug: Contraceptive switching
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive switching or discontinuation
Study: 38781634
Drug: Both switching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both switching and discontinuation
Study: 38781634
Drug: Discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation
Study: 38781634
Drug: Subsequent method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent method after discontinuation
Study: 38781664
Drug: Chlorthalidone/amiloride 25/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone/amiloride 25/5 mg
Study: 38781965
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ICIs) treatment, with or without chemotherapy, for front-/subsequent-line therapy.
Study: 38782015
Drug: Arimoclomol citrate
Normalized name: ARIMOCLOMOL CITRATE
DrugBank: Arimoclomol (DB05025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arimoclomol citrate 1200 mg/day (400 mg three times per day)
Study: 38782542
Drug: EVX-01 (personalized
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVX-01 (personalized peptide-based neoantigen vaccine)
Study: 38782609
Drug: Crushed venetoclax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed venetoclax tablets
Study: 38782609
Drug: Ground venetoclax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ground venetoclax tablets
Study: 38782609
Drug: Intact venetoclax
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact venetoclax tablets
Study: 38782726
Drug: Volenrelaxin (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volenrelaxin (intravenous or subcutaneous)
Study: 38782726
Drug: Volenrelaxin (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volenrelaxin (subcutaneous once weekly for 5 weeks)
Study: 38783176
Drug: MAF capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAF capsules
Study: 38783176
Drug: M capsules
Normalized name: Menofem Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: M capsules
Study: 38783205
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment program over 24 weeks
Study: 38783238
Drug: Nivolumab (anti-PD-1)
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (anti-PD-1) maintenance therapy discontinued early after achieving CR/PR
Study: 38783836
Drug: Computer-Based Training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-Based Training for Cognitive Behavioural Therapy (CBT4CBT)
Study: 38784165
Drug: Mobile app-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile app-based self-guided psychological intervention (Nałogometr 2.0) incorporating mindfulness techniques and Cognitive Behavioral Therapy (CBT) principles over three months.
Study: 38784617
Drug: LIFEwithIBD intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LIFEwithIBD intervention (Acceptance and Commitment Therapy and compassion-based intervention)
Study: 38785314
Drug: Enhanced hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced hydration (20 mL/kg body weight, one-third given via bolus and remainder over 8 hours)
Study: 38785314
Drug: Standard hydration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hydration (60 mL/h for 8 hours, followed by maintenance infusion of 40-80 mL/h for the subsequent 64 hours)
Study: 38785484
Drug: Ultrahypofractionated (UHF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrahypofractionated (UHF) MRI-guided radiotherapy on a 1.5 T MR-Linac with a dose of 42.7 Gy in seven fractions
Study: 38787562
Drug: Remote, pushed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote, pushed digital assessments and engagement (monthly text messaging about mental health, mental health assessments, and linkages to care)
Study: 38788175
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) treatment in good-grade aSAH (N = 232)
Study: 38788175
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) treatment in poor-grade aSAH (N = 162)
Study: 38788821
Drug: TEER with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEER with MitraClip device plus guideline-directed medical therapy (GDMT)
Study: 38788904
Drug: Intraprostatic injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraprostatic injection of 1 g of tranexamic acid (TXA) dissolved in 50 mL of 0.9% saline at multiple sites
Study: 38788904
Drug: 60 mL
Normalized name: Disposable Nurser 60 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mL saline injection (Control)
Study: 38788907
Drug: Adjuvant letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant letrozole 2.5 mg/day
Study: 38789134
Drug: Ferrous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous iron (Ferrous succinate sustained-release tablet 0.2 g corresponding to 70 mg of elemental iron) once daily for 12 weeks
Study: 38789134
Drug: Placebo (similar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (similar in colour, smell, and size to ferrous iron) once daily for 12 weeks
Study: 38789134
Drug: Ferrous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ferrous iron (Ferrous succinate sustained-release tablet 0.2 g)
Study: 38789142
Drug: Proactive e-alcohol
Normalized name: (E)-cinnamyl alcohol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive e-alcohol therapy
Study: 38789363
Drug: Maintenance of
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of beta-blockers
Study: 38789602
Drug: Epinephrine (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (0.03 mcg/kg/min)
Study: 38789602
Drug: Phenylephrine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (0.4 mcg/kg/min)
Study: 38789656
Drug: Rose geranium
Normalized name: ALCOHOL 62 mL in 100 mL TOPICAL SPRAY [All Good Rose Geranium Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rose geranium in sesame oil (RG) nasal spray, administered twice daily for 2 weeks
Study: 38789656
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (IS) nasal spray, administered twice daily for 2 weeks
Study: 38789924
Drug: Giredestrant plus
Normalized name: Giredestrant
DrugBank: Giredestrant (DB19125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Giredestrant plus fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC)
Study: 38789924
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus optional endocrine therapy (ET)
Study: 38790057
Drug: APG-1387 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: APG-1387 and anti-PD-1 antibody
Study: 38790900
Drug: Second-generation drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation drug-eluting stents (rDESs)
Study: 38793748
Drug: MVA-BN-Filo (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-BN-Filo (dose 1) and Ad26.ZEBOV (dose 2), administered intramuscularly 14 days apart
Study: 38793748
Drug: Saline/placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline/placebo (two doses administered intramuscularly 14 days apart)
Study: 38793748
Drug: MVA-BN-Filo (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA-BN-Filo (dose 1) and Ad26.ZEBOV (dose 2)
Study: 38794715
Drug: Standard Mediterranean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Mediterranean dietary pattern with daily energy restriction (DER + MED)
Study: 38795087
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation (OAC) at baseline
Study: 38795108
Drug: TEER +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEER + guideline-directed medical therapy (GDMT)
Study: 38795703
Drug: COX inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: COX inhibitors plus anti-PD-1 therapy
Study: 38796326
Drug: High-dose rotavirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rotavirus inactivated vaccine
Study: 38796326
Drug: Medium-dose rotavirus
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose rotavirus inactivated vaccine
Study: 38796326
Drug: Low-dose rotavirus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rotavirus inactivated vaccine
Study: 38796422
Drug: Apalutamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide plus androgen deprivation therapy (ADT) for 6 cycles
Study: 38796500
Drug: Oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotics and mechanical bowel preparation
Study: 38796619
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg Conbercept
Study: 38796619
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg Aflibercept
Study: 38796655
Drug: Clazakizumab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clazakizumab (monoclonal antibody targeting IL-6 ligand)
Study: 38797114
Drug: Nurse-led multidomain
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led multidomain intervention including risk factors assessment, education, antiemetics, dietary strategies, and relaxation therapy
Study: 38797183
Drug: Doxycycline PEP
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline PEP (two pills of 100 mg each orally within 72 h after condomless sex, with no more than three doses of 200 mg per week)
Study: 38797183
Drug: 4CMenB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB vaccine (two intramuscular injections at enrolment and at 2 months)
Study: 38797190
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg/kg intravenously on day 2 or 3, then once every 3 weeks for 2 years) + low-dose, single-fraction radiotherapy (8 Gy/1 fx)